Investing in the Next Generation of RNA Therapeutics
Apterna is developing REGEN001, a liver-directed RNA therapeutic designed to restore liver function in patients whose livers are too damaged for curative surgery or transplant. The programme begins with liver cancer patients denied surgery because liver reserve is too poor, with broader future relevance across cirrhosis, transplant avoidance, and fatty liver disease as evidence builds.
Apterna’s investment case is built around a rare combination in early-stage biotech: a clearly defined unmet need, a proven therapeutic foundation, a focused and measurable first indication, and a broader expansion pathway across the liver disease continuum.
REGEN001 begins with liver cancer patients whose tumours may be removable, but whose liver reserve is too poor to tolerate surgery. This creates a high-need first setting with a stark difference between palliative and curative outcomes.
The programme is built on a validated GalNAc-siRNA therapeutic foundation, allowing innovation to focus on the biology and clinical opportunity rather than on inventing an entirely new delivery system from scratch.
Apterna starts with surgical unlock, then expands into cirrhosis and transplant avoidance, and over time into fatty liver disease and obesity-related liver dysfunction, creating a focused entry point with substantial long-term upside.
The company’s model is to advance through the key proof-of-concept milestones internally, then partner from strength for broader clinical development, scale, and global reach.
Most existing therapies in liver disease were designed for different problems. Cancer drugs target the tumour. GLP-1 therapies address metabolic inputs in earlier-stage disease. Locoregional procedures treat anatomy. None is designed to restore the liver function needed to reopen curative pathways in the patients who need it most.
What makes Apterna different is that REGEN001 is being developed as a new category of liver functional restoration, beginning where the survival gap is most dramatic and then extending across much larger adjacent liver markets over time.
Current interventions may slow disease, reduce fat, or treat the tumour, but they do not restore the underlying liver function required to reopen curative options.
The lead setting is tightly defined and clinically urgent, creating a clearer proof-of-concept pathway than starting in a broad, diffuse market.
Apterna is not trying to be incrementally better in a crowded field. It is pursuing a new therapeutic logic in an area where the need is still fundamentally unmet.
By starting in a focused surgical setting and expanding across broader liver disease, the programme combines near-term clarity with long-term strategic upside.
Apterna is advancing REGEN001 through a stage-gated development plan designed to validate the biology early, manage risk carefully, and progress efficiently towards clinical proof of concept. The most informative risks are addressed first, before major capital is committed.
Stage-gated development with early biological validation and disciplined progression.
A focused first indication designed to generate meaningful proof of concept before broader expansion.
Advance through key value-creating milestones, then partner from strength for scale and reach.
Optimisation of the lead candidate and early biological validation in laboratory systems to confirm that the programme is producing the intended effect before more expensive development begins.
Disease-relevant testing in animal models and confirmation in human organoid systems to establish that the biology translates beyond the laboratory bench.
A formal decision point followed by toxicology, CMC initiation, and regulatory groundwork if the programme earns the right to advance into the next phase.
Clinical entry through CTA / IND preparation and early dose-escalation execution, designed to begin generating human safety and translational data.
Clinical and pharmacodynamic readout intended to demonstrate proof of concept and support strategic partnering for broader development, scale, and reach.
REGEN001 begins with a tightly focused first market: liver cancer patients denied curative surgery because their liver function is too poor. From there, the same therapeutic logic is intended to extend into cirrhosis and transplant avoidance, and over time into the far larger fatty liver and obesity-related liver disease market.
The first clinical entry point is a sharply defined setting where poor liver reserve prevents potentially curative surgery.
Once validated in the lead setting, the programme can extend into advanced liver dysfunction where restoring function may delay or reduce transplant dependence.
The longer-term expansion opportunity is the largest liver disease market, where deeper liver repair may complement metabolic therapies as disease progresses.
Apterna is led by founders and advisers whose backgrounds combine frontline clinical insight, therapeutic innovation, drug development, and company building. That matters because REGEN001 sits at the intersection of all four: a serious clinical problem, a translational RNA strategy, a staged development pathway, and a build-to-partner business model.
The team brings experience across hepatobiliary surgery, RNA therapeutics, regulatory strategy, clinical execution, and high-value commercial transactions. For investors, this means Apterna is being built by people who understand how to move from scientific insight to development discipline, and from early validation to strategic partnering.
This is not simply academic credibility. It is leadership shaped by real company creation, clinical translation, operational delivery, and partnership outcomes. That combination gives Apterna both scientific legitimacy and a practical route towards meaningful value inflection.
The leadership profile is grounded in real hepatobiliary medicine and translational science, helping ensure that the programme is shaped by clinical reality rather than abstract platform theory.
Apterna is being advanced with the mindset of a company designed to reach defined value-creating milestones efficiently, with clear decision points and practical development logic.
The team’s combined experience in innovation, company creation, and partnering supports a model built to create a transaction-ready asset with broader appeal across the liver disease landscape.
Clinical
Leadership rooted in real-world hepatobiliary and liver disease practice.
Translational
Experience spanning discovery, development strategy, and clinical progression.
Strategic
Built by people who understand partnering, execution, and long-term value creation.
Value creation in Apterna is designed to come from staged de-risking. Early biological proof, disease-relevant validation, clinical entry, and proof-of-concept data are intended to increase strategic leverage at each step.
The principal objective is to create a transaction-ready asset by the time the programme reaches meaningful proof of concept. Importantly, the broader liver disease narrative increases the value of the lead asset rather than distracting from it.
A successful proof of concept in the initial surgical setting would not be viewed in isolation. It would support expansion into adjacent liver markets using the same underlying therapeutic logic.
The initial surgical setting is intended to create a focused and credible proof-of-concept pathway with a clinically meaningful outcome.
As the programme advances through biological validation, clinical entry, and early human data, the aim is to improve negotiating leverage for future partnering.
Success in one liver setting is intended to reinforce relevance across cirrhosis, transplant avoidance, and fatty liver disease over time.
Establish that the programme works in the relevant systems and earns the right to advance.
Move into human testing with a clear translational logic and an efficiently staged development plan.
Generate the dataset designed to demonstrate meaningful clinical and strategic relevance.
Use the de-risked asset and broader liver narrative to support high-value strategic discussions.
investors [at] apterna.com
partnerships [at] apterna.com
London, United Kingdom
Apterna stands at the forefront of precision RNA delivery, advancing a clinically grounded, scientifically de-risked strategy toward transformative therapies for liver and brain disease. We invite investors and partners who share our vision of responsible innovation to join us in shaping the future of RNA therapeutics.
